Executive Vice President, Oncology Therapeutics
. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head. He was instrumental in expanding Gilead’s oncology program with the acquisition of Kite Pharma, establishing the company as a leader in the field of cellular therapy. He has also guided the strategy and development of Gilead’s broader oncology pipeline during his tenure. Prior to joining Gilead, Dr. Riva served as Head, Global Oncology Development at Novartis, where he oversaw the development and worldwide regulatory approval of multiple compounds in a variety of tumor types. He received his bachelor’s degree in Medicine and a Certificate Board in Oncology/Hematology from the School of Medicine of Milan. Earlier in his career, he worked as a physician, treating patients with hematological malignancies at the University Hospital of Milan.